Jürke Kotthaus

发表

Arylazoamidoximes and Related Compounds as NO‐modulators

D. Schade, B. Clement, A. Schröder, 2010, Archiv der Pharmazie.

Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads.

D. Schade, E. Beitz, B. Clement, 2008, Bioorganic & medicinal chemistry.

Synthetic approaches to N(delta)-methylated L-arginine, N(omega)-hydroxy-L-arginine, L-citrulline, and N(delta)-cyano-L-ornithine.

D. Schade, B. Clement, Jürke Kotthaus, 2008, The Journal of organic chemistry.

Nδ-Methylated l-arginine derivatives and their effects on the nitric oxide generating system

D. Schade, E. Beitz, B. Clement, 2008 .

New Prodrugs of the Antiprotozoal Drug Pentamidine

D. Schade, B. Clement, W. Raasch, 2011, ChemMedChem.

Synthesis and biological evaluation of L-valine-amidoximeesters as double prodrugs of amidines.

S. Wolffram, D. Schade, B. Clement, 2011, Bioorganic & medicinal chemistry.

Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.

O. Koch, D. Schade, M. Schmidtke, 2014, Journal of medicinal chemistry.

Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.

D. Schade, M. Schmidtke, A. Hoffmann, 2015, Journal of pharmaceutical sciences.

Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.

D. Schade, B. Clement, J. Kotthaus, 2011, Organic & biomolecular chemistry.

Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease.

D. Schade, B. Clement, Jürke Kotthaus, 2010, Pharmacology & therapeutics.

Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).

D. Garbe‐Schönberg, F. Bittner, D. Schade, 2011, The Biochemical journal.

The Peptidylglycine α‐Amidating Monooxygenase (PAM): A Novel Prodrug Strategy for Amidoximes and N‐Hydroxyguanidines?

D. Schade, B. Clement, J. Kotthaus, 2009, ChemMedChem.

Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).

D. Garbe‐Schönberg, F. Bittner, D. Schade, 2011, The Biochemical journal.